Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Persistent Losses ⢠Negative Cash Flow ADPT has strong liquidity and healthy gross margins, but persistent operating losses, negative cash flow, and weak returns keep the financial picture risky despite manageable leverage.
Price Behavior
Key Price Behavior Insights: ⢠Reclaimed support ⢠Near resistance ⢠Volatility risk Support Level: $13.80â$14.00 Resistance Level: $14.50â$14.60 ADPT has improved over the last month with higher closes and reclaimed support around $13.80â$14.00, but it still faces near-term resistance at $14.50â$14.60 and remains vulnerable to volatility until that zone breaks.
Sentiment & News
Key News Insights: ⢠Insider Selling ⢠Revenue Growth ⢠Earnings Ahead Adaptive Biotechnologies saw heavy insider and institutional selling through MarchâApril 2026 even as it reported strong revenue growth and prepared to release Q1 results, creating a mixed but cautionary setup for ADPT. #insider-sellingâ #revenue-growthâ
AI Summary
ADPT's investment case has shifted from a speculative turnaround to a real MRD-led operating story, with strong growth, improving gross margins, and reimbursement support suggesting scalable cash-generation potential, but the stock still hinges on whether that momentum can outpace companywide losses, debt, and insider-selling overhangs.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |